MedTrace Logo

Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants

NCT07236411 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-05-05

No results posted yet for this study

Summary

The purpose of this study is to determine the absolute bioavailability of SC administered cizutamig in healthy adult participants.

Conditions

  • Healthy Participants Study

Interventions

BIOLOGICAL

cizutamig

cizutamig will be dosed SC or IV according to the assigned cohort

OTHER

Placebo

placebo will be dosed IV or SC according to the assigned cohort

Sponsors & Collaborators

  • Candid Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-04
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07236411 on ClinicalTrials.gov